{
    "clinical_study": {
        "@rank": "136109", 
        "arm_group": {
            "arm_group_label": "Trivalent Inactivated Influenza Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "Single dose, intramuscular injection from a pre-filled syringe\nWHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:\nan A/California/7/2009 (H1N1)pdm09-like virus;\nan A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
        }, 
        "brief_summary": {
            "textblock": "The overall aim of this project is to evaluate the immunogenicity of TIV vaccination in\n      HIV-infected non-pregnant women in 2013. Safety data including solicited local and systemic\n      reactions to the vaccine will also be assessed."
        }, 
        "brief_title": "Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Influenza", 
            "Human Immunodeficiency Virus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Influenza, Human"
            ]
        }, 
        "detailed_description": {
            "textblock": "Schedule of Events\n\n      Visit 1 (enrollment) Informed Consent Form (ICF) signed Inclusion/ exclusion/ Withdrawal\n      criteria Medical history Targeted physical exam Blood draw TIV administered Diary card\n      dispensed\n\n      Local/ systematic reactions\n\n      Visit 2: 1 month post enrolment (28-35 days) Inclusion/ exclusion/ Withdrawal criteria\n      Medical history Targeted physical exam Blood draw Diary card collected Local/ systematic\n      reactions reviewed"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        (i) Documented to be HIV-1 infected on one assay used in the Prevention of Mother to Child\n        Transmission (PMTCT)/ other program undertaken within 12 weeks of study enrolment.\n\n          -  Able to understand and comply with planned study procedures.\n\n          -  Provides written informed consent prior to initiation of study.\n\n          -  Not pregnant at time of enrolment (confirmed by urine testing). If pregnant in past\n             year, participant must be at least 6 months post delivery at time of enrolment.\n\n          -  Women age \u2265 18 years to < 39 years.\n\n        Exclusion Criteria:\n\n          -  Receipt of TIV, other than through the study, during the current and previous two\n             influenza seasons, documented by medical history or record.\n\n          -  Receipt of any live licensed vaccine \u2264 28 days or any other vaccine (except for\n             tetanus toxoid vaccine) \u2264 14 days prior to study-vaccine.\n\n          -  Receipt of a non-licensed agent (vaccine, drug, biologic, device, blood product, or\n             medication) \u2264 28 days prior to vaccination in this study, unless study approval is\n             obtained.\n\n          -  Any significant (in the opinion of the site investigator) acute illness and/or oral\n             temperature greater than or equal to 38 degrees C \u2264 24 hours prior to study entry.\n\n          -  Use of anti-cancer systemic chemotherapy or radiation therapy \u2264 48 weeks of study\n             enrollment, or has immunosuppression as a result of an underlying illness or\n             treatment.\n\n          -  Long term use of glucocorticoids, including oral or parenteral prednisone \u2265 20 mg/day\n             or equivalent for more than 2 consecutive weeks (or 2 weeks total) \u2264 12 weeks of\n             study entry, or high-dose inhaled steroids (>800 mcg/day of beclomethasone\n             dipropionate or equivalent) \u2264 12 weeks before study entry (nasal and topical steroids\n             are allowed).\n\n          -  Receipt of immunoglobulin or other blood products (with exception of Rho D immune\n             globulin) \u2264 12 weeks prior to enrollment in this study or is scheduled to receive\n             immunoglobulin or other blood products.\n\n          -  Receipt of Interleukin 2, IFN, GMCSF or other immune mediators \u2264 12 weeks before\n             enrollment.\n\n          -  Uncontrolled major psychiatric disorder.\n\n          -  History of a severe adverse reaction to previous TIV.\n\n          -  Any condition that would, in the opinion of the site investigator, place the subject\n             at an unacceptable risk of injury or render the subject unable to meet the\n             requirements of the protocol."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "39 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812980", 
            "org_study_id": "MatFlu_HIVpos_nonpregnant"
        }, 
        "intervention": {
            "arm_group_label": "Trivalent Inactivated Influenza Vaccine", 
            "description": "WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:\nan A/California/7/2009 (H1N1)pdm09-like virus;\nan A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.", 
            "intervention_name": "Trivalent Inactivated Influenza Vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Vaxigrip"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Influenza", 
            "Human Immunodeficiency Virus"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Soweto", 
                    "country": "South Africa", 
                    "state": "Gauteng"
                }, 
                "name": "Nrf/Dst Vpd Rmpru"
            }
        }, 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_arms": "1", 
        "official_title": "Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV- Infected Women: An Open Label Trial.", 
        "overall_official": {
            "affiliation": "University of Witwatersrand, South Africa", 
            "last_name": "Shabir A Madhi, PHD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Africa: Human Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Humoral immunity will be measured by hemagglutination inhibition (HAI) assay, which has been extensively used for this purpose. In healthy individuals, HAI titers \u22651:10 indicate presence of influenza-specific antibodies and \u22651:40 protection against infection and disease. In this study we will use the following definitions to assess the humoral immune response to TIV: HAI titers <1:10 = seronegative; HAI titers \u22651:10 = seropositive; HAI titers \u22651:40 = sero-protective titers; and sero-conversion will be defined as HAI titers from <1:10 to \u22651:40 or \u22654-fold increase if pre-vaccination titers were \u22651:10.", 
            "measure": "Immunogenicity of Trivalent Influenza Vaccine (TIV)by measuring Hemagglutination Inhibition Assays (HAI)", 
            "safety_issue": "No", 
            "time_frame": "one month post vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812980"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Witwatersrand, South Africa", 
            "investigator_full_name": "Michelle Groome", 
            "investigator_title": "Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "T-lymphocyte activation assays will be performed using state-of-the art polychromatic flow cytometry.  The T- and B-cell phenotypes are assessed by flow cytometry using freshly thawed Peripheral Blood Mononuclear Cells (PBMC). Cells are stained using monoclonal antibodies against the comparator molecules.", 
                "measure": "impact of vaccination on T-cell activation and on T- and B-cell subpopulations", 
                "safety_issue": "No", 
                "time_frame": "one month post vaccination"
            }, 
            {
                "description": "Interferon(IFN)Enzyme Linked Immuno Spot (ELISPOT) responses will be used to assess CMI responses to influenza vaccines.PBMCs will be separated and stimulated with  influenza virus corresponding to the vaccine strains. Spots will be visualized with a ELISPOT plate reader. Results will be reported as Spot Forming Cells(SFC)/106 PBMCs.", 
                "measure": "Impact of Vaccination of Cell Mediated Immune (CMI) Responses", 
                "safety_issue": "No", 
                "time_frame": "one month post vaccination"
            }, 
            {
                "description": "Participants will remain in the clinic for at least 30 minutes after vaccination so that clinic personnel can observe participants for any potential adverse reactions.Report of vaccine-related local (redness, swelling, tenderness, itching,) and systemic (fever, malaise, myalgia, nausea, headache, rash) adverse events will be solicited at day 7 and day 28.", 
                "measure": "Local and Systemic solicited reactions to TIV", 
                "safety_issue": "Yes", 
                "time_frame": "1 week and one month post vaccination"
            }, 
            {
                "description": "Safety and tolerability of the study vaccine will be monitored by means of Adverse Events (AEs) and toxicity reports presenting laboratory and clinical data.Toxicities will be classified by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events,", 
                "measure": "safety outcome measures of TIV", 
                "safety_issue": "Yes", 
                "time_frame": "within one month post vaccination"
            }
        ], 
        "source": "University of Witwatersrand, South Africa", 
        "sponsors": {
            "collaborator": {
                "agency": "Bill and Melinda Gates Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Witwatersrand, South Africa", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}